The at-home stroke rehab device is set to expand in the US, with further additions to its suite of products planned
Digital neuro-rehabilitation platform Neurofenix, which is helping to revolutionise remote rehabilitation for stroke patients, has secured $7million to help fuel its expansion and fund clinical trials in the United States.
Neurofenix, founded in 2016, uses sensor technology to improve patient recovery outcomes and widen options in neuro-rehab through its ability to deliver clinical grade rehabilitation remotely.
Its offering currently focuses on arm and hand therapy through its NeuroBall device, supported by its telemedicine platform Neurofenix Portal.
Now, to help expand its product line further and invest in expansion into the United States – including clinical trials – Neurofenix has secured $7million in Series A funding, in a round led by AlbionVC, with additional participation by HTH, InHealth Ventures, and existing investors.
Guillem Singla Buxarrais, CEO of Neurofenix, who co-founded the business with Dimitrios Athanasiou, said: “Over the last six years, we have been creating and developing our patient-centric sensor-based technology and platform to transform neuro-rehab.
“In clinical studies, NeuroBall was proven to motivate patients to do hundreds of movement repetitions independently at home, which led to significant improvements in the range of motion, reduction of arm pain and return to daily activities using their arm and hand after a stroke.
“This has proven transformative to neuro-rehab as previously patients would not have access to in-person physical or occupational therapy due to factors such as insurance, financial, transportation and health barriers.
“We’re excited to partner with AlbionVC, HTH, and InHealth Ventures, and are hugely grateful for their support to scale our unique neurological therapeutics platform that we believe will change the world of neuro-rehab.”